ATE367817T1 - Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung - Google Patents

Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung

Info

Publication number
ATE367817T1
ATE367817T1 AT02722637T AT02722637T ATE367817T1 AT E367817 T1 ATE367817 T1 AT E367817T1 AT 02722637 T AT02722637 T AT 02722637T AT 02722637 T AT02722637 T AT 02722637T AT E367817 T1 ATE367817 T1 AT E367817T1
Authority
AT
Austria
Prior art keywords
antgesgesgens
postpone
infertility treatment
maturation during
endometrial maturation
Prior art date
Application number
AT02722637T
Other languages
English (en)
Inventor
Christa Hegele-Hartung
Holger Hess-Stumpp
Henning Beier
Claudia Krusche
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/801,925 external-priority patent/US20020143000A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE367817T1 publication Critical patent/ATE367817T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT02722637T 2001-01-09 2002-01-09 Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung ATE367817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75628601A 2001-01-09 2001-01-09
US09/801,925 US20020143000A1 (en) 2001-01-09 2001-03-09 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment

Publications (1)

Publication Number Publication Date
ATE367817T1 true ATE367817T1 (de) 2007-08-15

Family

ID=27116200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02722637T ATE367817T1 (de) 2001-01-09 2002-01-09 Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung

Country Status (25)

Country Link
US (1) US20040152684A1 (de)
EP (1) EP1365765B1 (de)
JP (1) JP2004520411A (de)
CN (1) CN1244329C (de)
AR (1) AR032390A1 (de)
AT (1) ATE367817T1 (de)
AU (1) AU2002253488B2 (de)
BG (1) BG107977A (de)
BR (1) BR0206367A (de)
CA (1) CA2433776A1 (de)
CZ (1) CZ20031864A3 (de)
DE (1) DE60221359T2 (de)
DK (1) DK1365765T3 (de)
EE (1) EE200300321A (de)
ES (1) ES2290284T3 (de)
HK (1) HK1065953A1 (de)
HR (1) HRP20030628A2 (de)
HU (1) HUP0302632A2 (de)
IL (1) IL156729A0 (de)
MX (1) MXPA03006156A (de)
NO (1) NO20033125L (de)
NZ (1) NZ526908A (de)
PL (1) PL361689A1 (de)
SK (1) SK8612003A3 (de)
WO (1) WO2002067910A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP3037101B1 (de) * 2014-12-22 2019-03-06 Ferring B.V. Oxytocinrezeptorantagonistentherapie in der Lutealphase für Implantation und Schwangerschaft bei mit Technologien zur unterstützten Fortpflanzung behandelten Frauen
EP3214092A1 (de) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs vom selektiven progesteronrezeptormodulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-on

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19860719A1 (de) * 1998-12-23 2000-06-29 Schering Ag Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen

Also Published As

Publication number Publication date
HK1065953A1 (en) 2005-03-11
EE200300321A (et) 2003-10-15
ES2290284T3 (es) 2008-02-16
CZ20031864A3 (en) 2004-03-17
NZ526908A (en) 2005-07-29
BG107977A (bg) 2004-08-31
DE60221359T2 (de) 2008-04-17
PL361689A1 (en) 2004-10-04
EP1365765A2 (de) 2003-12-03
EP1365765B1 (de) 2007-07-25
NO20033125D0 (no) 2003-07-08
WO2002067910A2 (en) 2002-09-06
CN1244329C (zh) 2006-03-08
US20040152684A1 (en) 2004-08-05
BR0206367A (pt) 2003-12-23
CN1496263A (zh) 2004-05-12
AR032390A1 (es) 2003-11-05
AU2002253488B2 (en) 2007-02-15
CA2433776A1 (en) 2002-09-06
DK1365765T3 (da) 2007-10-29
HUP0302632A2 (hu) 2003-11-28
IL156729A0 (en) 2004-02-08
NO20033125L (no) 2003-09-09
MXPA03006156A (es) 2003-09-16
JP2004520411A (ja) 2004-07-08
SK8612003A3 (en) 2004-03-02
DE60221359D1 (de) 2007-09-06
WO2002067910A3 (en) 2003-02-06
HRP20030628A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
DE60120114D1 (de) Verfahren zur Verbesserung der Knochenmineralisierung
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
ATE306933T1 (de) Verfahren zur herabregulierung von amyloid
NO20025814L (no) Fremgangsmåte ved brönnfullföring
DE60235578D1 (de) Verfahren zur reifenuntersuchung
DE60329015D1 (de) Verfahren zur hemmung der acrylamidbildungund seine verwendung
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
ATE382631T1 (de) Verfahren zur herstellung von virusinaktiviertem humanem gammaglobulin g
DE60223089D1 (de) Verfahren zur Signalisierung von Konfigurationsparametern physikalischer Kanäle
DE60221972D1 (de) Verfahren zur gewichtsverminderung von gipsbauplatten
DE50205653D1 (de) Verfahren zur festlegung von zeitpunkt und umfang von wartungsvorgängen
ATE413375T1 (de) Retinoide zur behandlung von emphysem
ATE505811T1 (de) Verfahren zur nassbehandlung von scheibenförmigen gegenständen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE367817T1 (de) Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung
DE60104976D1 (de) Verfahren zur Bereitstellung von Dienstleistungen
DE50206619D1 (de) Reinigungsmaschine und Verfahren zur Reinigung von Schotter
ATE337787T1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60213460D1 (de) Verfahren zur wiederverwendung von stahlblechschrott
ATE311898T1 (de) Zusammensetzungen zur entfernung von menschlichem cerumen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
DE60103503D1 (de) Verwendung von fsh zur behandlung von infertilität
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1365765

Country of ref document: EP

REN Ceased due to non-payment of the annual fee